High throughput, low cost phenotypic AST/MIC system giving results in 3 hours from positive blood culture. Can also be used with urine and sterile fluids samples, as well as swabs.

Cost per test and throughput comparable with current disk diffusion, but delivering EUCAST-compliant results in 3 hours, instead of 48, for Gram-negative positive blood cultures. Cost per test likely to be lower than current workflow (c. 25 Euros per patient sample, including MIC). one machine can process 30 patient blood samples per shift, enough for most labs. Capital equipment cost is under 25,000 Euros.

  • Antimicrobial stewardship
  • Microbial diagnostics
  • Infection prevention
  • Antimicrobial compound/strategy
  • Removal antibiotics/bacteria

  • Bacteria
  • Fungi
  • Yeasts
  • Viruses
  • Parasites

  • Human
  • Veterinary
  • AgriFood
  • Environmental
  • Other

Development stage:
  • Validation
  • Research
  • Development
  • Market entry
  • Marketed product

  • Company
  • Academia
  • Institute
  • NGO
  • Government

  • License
  • Co-develop
  • Sell
  • Outsource
  • Joint Venture

Funding organisation:
  • CARB-X
  • FIND
  • OTHER / NA

Infectious disease area:
  • UTI
  • STI
  • BSI
  • RTI
  • CNSI
  • SSI
  • GII
  • SSTI
  • IAI

Geographic origin:
  • Eurasia
  • North America
  • South America
  • Africa
  • Oceania

We are looking for Distributors in the EU and US. Also looking for research partners to demonstrate the capabilities of the technology in other areas.

iFAST has developed a low-cost, high throughput, system for AST and MIC testing of blood, urine and sterile fluid samples that gives results in 3 hours, direct from a positive blood culture. Our system measures the electrical properties of 5,000 individual bacteria per sample that has been exposed to each antibiotic of interest, and then compares these data with the unexposed control sample to determine susceptibility and resistance. The result is a fully EUCAST-compliant AST/MIC result for up to 20 different drugs per panel.
After raising our seed investment in January 2023, we have developed two generations of demonstrators and are now engaged in multiple hospital evaluations, currently demonstrating better than 95% concordance with disk diffusion.
We are interested to discuss collaborations in various areas, including hospital trials in the EU and US, as well as potential research work on Gram positive bacteria, fungi and phage.


What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!

Keep me informed